000			05106nam a22004215i 4500
001			100841
003			ESmaUEC
005			20230102113013.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			180502s2018 gw | s |||| 0|eng d
020			_a9783319754024 _9
024	7		_a10.1007/978-3-319-75402-4 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
050		4	_aRE661.D3 2018 EB
245	0	0	_aRetinal Degenerative Diseases : _bMechanisms and Experimental Therapy _cedited by John D. Ash, Robert E. Anderson, Matthew M. LaVail, Catherine Bowes Rickman, Joe G. Hollyfield, Christian Grimm.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2018
300			_a1 recurso en línea (XLII, 669 páginas 142 ilustraciones,93 ilustraciones a color)
336			_aTexto _btxt _2rdacontent
347			_atext file _bPDF _2
490	0		_aAdvances in Experimental Medicine and Biology _x0065-2598 _v1074
520	3		_aThe blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2014. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2018 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.
650		7	_aDegeneración macular _2embne _9670079
650		7	_aOftalmología _2embne _9139186
700	1		_aAsh, John _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/nb2014010812 _1http://viaf.org/viaf/286188493 _910139
700	1		_aAnderson, Robert E. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n82240171 _1http://viaf.org/viaf/91233325 _984493
700	1		_aLaVail, Matthew M. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n85025824 _1http://viaf.org/viaf/93095331 _984494
700	1		_aBowes Rickman, Catherine. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _1http://viaf.org/viaf/308793214 _984495
700	1		_aHollyfield, Joe G. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n81097438 _1http://viaf.org/viaf/233392052 _984492
700	1		_aGrimm, Christian. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n91074521 _1http://viaf.org/viaf/61938004 _98523
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
776	0	8	_iEdición impresa: _z9783319754017
776	0	8	_iEdición impresa: _z9783319754031
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-75402-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
490	0		_aBiomedical and Life Sciences (Springer-11642)
942			_2lcc
998			_aSI _a_alco _a_vill _b07/2019 _cm _dz _ef _feng _ggw _h0
999			_c100841 _d100841 _x1